Drug Profile

HBM 1007

Alternative Names: HBM-1007; R 1007

Latest Information Update: 19 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Harbour BioMed
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

19 Dec 2023 HBM 1007 is still in preclinical develpoment for Solid tumours in China (Parenteral) (Harbour BioMed pipeline, December 2023)
28 Oct 2023 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
31 Aug 2022 Harbour BioMed announces intention to submit IND applications for Solid tumours in the end of 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com